Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Payables (2019 - 2025)

Biodesix's Payables history spans 7 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Payables rose 39.32% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, up 39.32%, while the annual FY2025 figure was $3.1 million, 39.32% up from the prior year.
  • Payables reached $3.1 million in Q4 2025 per BDSX's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.4 million in Q3 2022 to a low of $1.6 million in Q1 2023.
  • Average Payables over 5 years is $4.1 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 94.62% in 2021, then surged 914.44% in 2022.
  • A 5-year view of Payables shows it stood at $1.7 million in 2021, then grew by 3.15% to $1.7 million in 2022, then skyrocketed by 71.86% to $3.0 million in 2023, then fell by 25.67% to $2.2 million in 2024, then soared by 39.32% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Payables are $3.1 million (Q4 2025), $3.6 million (Q3 2025), and $3.0 million (Q2 2025).